

REGISTRATION LINK: <https://marylandpatientsafety.org/medicationsafetyconf/>



## OBJECTIVES

- Discuss innovative strategies and key collaborations necessary to improve workflows and address gaps in medication safety.
- Describe how to optimize your technology, including computerized clinical decision support, to prevent medication errors and adverse drug events.
- Discuss recent significant medication safety issues reported to ISMP and related error prevention and mitigation strategies.

## AGENDA

12:00 – 12:15 p.m.	<b>Welcome: Medication Safety Priorities and Support from MPSC</b> <i>Stephanie Peditto</i> President & CEO, Maryland Patient Safety Center
12:15 – 1:00 p.m.	<b>AHRQ Computerized Clinical Decision Support To Prevent Medication Errors and Adverse Drug Events</b> <i>Ania Syrowatka, PhD</i> Lead Investigator, Division of General Internal Medicine & Primary Care, Brigham and Women's Hospital
1:00 – 2:00 p.m.	<b>Medication Safety and Reporting Practices in Acute Care: Strategies to Make it Safer for Healthcare Organizations</b> <i>Andrea Schuermann, RN, MSN</i> Director of Quality, Orlando Health South Seminole Hospital <i>Laura Arkin, RN, MSN</i> Director of Quality, Orlando Health Jewett Orthopedic Institute
2:00 – 2:15 p.m.	<b>BREAK</b>
2:15 – 3:15 p.m.	<b>Medication Reconciliation is Everyone's Job</b> <i>Sarah Bajorek, PharmD</i> Assistant Chief Pharmacy Officer-Ambulatory Care, University of California- Davis Health <i>Donna Leang, PharmD</i> Medication Safety Health System Manager-Transitions of Care, Cedars Sinai Health System
3:15 – 4:15 p.m.	<b>ISMP Significant Medication Safety Issues</b> <i>Rita K. Jew, Pharm.D., MBA, BCPPS, FASHP</i> President, Institute for Safe Medication Practices
4:15 – 4:30 p.m.	<b>Wrap Up, Evaluation, Next Step</b>

AGENDA IS SUBJECT TO CHANGE

This educational activity is jointly provided by Maryland Patient Safety Center and AXIS Medical Education

## ACCREDITED CONTINUING EDUCATION



### Accreditation Statement

In support of improving patient care, this activity has been planned and implemented by AXIS Medical Education and Maryland Patient Safety Center. AXIS Medical Education is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.



This activity was planned by and for the healthcare team, and learners will receive 3.75 Interprofessional Continuing Education (IPCE) credit for learning and change.

### Credit Designation for Pharmacists

This application-based activity is approved for 3.75 contact hours of continuing pharmacy education credit  
JA4008106-9999-24-066-L05-P

### Credit Designation for Nursing

AXIS Medical Education designates this continuing nursing education activity for 3.75 contact hours.  
Learners are advised that accredited status does not imply endorsement by the provider or ANCC of any commercial products displayed in conjunction with an activity.

### Quality Professionals

This program is pending approval by the National Association for Healthcare Quality (NAHQ) to provide CPHQ CE credit.

### AXIS Contact Information

For information about the accreditation of this program please contact AXIS at [info@axismeded.org](mailto:info@axismeded.org).

### Disclosure of Relevant Financial Relationships

AXIS Medical Education requires faculty, instructors, authors, planners, directors, managers, peer reviewers, and other individuals who are in a position to control the content of this activity to disclose all personal financial relationships they may have in the past 24 months with ineligible companies. An ineligible entity is any organization whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients. All relevant financial relationships are identified and mitigated prior to initiation of the planning phase for an activity.

AXIS has mitigated and disclosed to learners all relevant financial relationships disclosed by staff, planners, faculty/authors, peer reviewers, or others in control of content for this activity. Disclosure of a relationship is not intended to suggest or condone bias in any presentation but is made to provide participants with information that might be of potential importance to their evaluation of a presentation or activity. Disclosure information for faculty, authors, course directors, planners, peer reviewers, and/or relevant staff is provided with this activity.

The faculty reported the following relevant financial relationships or relationships they have with ineligible companies of any amount during the past 24 months.

Name of Faculty or Presenter	Reported Financial Relationship
Ania Syrowatka, PhD	Grant salary support to organization from IBM Watson Health (now Merative) and Hillrom (now part of Baxter). Relationships have ended.
Andrea Schuermann, RN, MSN	Nothing to disclose
Laura Arkin, RN, MSN	Nothing to disclose
Sarah Bajorek, PharmD	Nothing to disclose
Donna Leang, PharmD	Nothing to disclose
Rita Jew, PharmD	Advisor: TB Alliance. Common Stock: Amerisource Bergen, Arrowhead Pharmaceuticals, Gilead, GSK, Novavax, TeleDoc, VaxArt, and Vikings Therapeutics.

The following directors, planners, managers, and peer reviewers reported no financial relationships they have with any ineligible company of any amount during the past 24 months:

Name of Planner/Manager/Peer Reviewer	Reported Financial Relationship
Adriane Burgess, RN	Nothing to Disclose
Bonnie DiPietro, RN	Nothing to disclose
Ifeanyi Egbunike-Chukwuma, Pharm D	Nothing to disclose
Stephanie Peditto	Nothing to disclose
Dee Morgillo, MEd, MTIASCP, CHCP	Nothing to disclose

### Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed in this activity should not be used by clinicians without evaluation of patient conditions and possible contraindications on dangers in use, review of any applicable manufacturer's product information, and comparison with recommendations of other authorities.

### Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

### Requirements for credit:

- Attend/participate in the educational activity and review all course materials.
- Complete the CE Declaration form online by **11:59 pm ET December 15, 2024**. Instructions will be provided. If you do not enter the online portal by the above date, you will not be able to retrieve your statement of participation.
- Upon successful completion of the online form, your statement of completion will be presented to you to print. For pharmacists, your record will be automatically uploaded to CPE Monitor.